18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis
- First Online:
- Cite this article as:
- Keijsers, R.G., Verzijlbergen, F.J., Oyen, W.J. et al. Eur J Nucl Med Mol Imaging (2009) 36: 1131. doi:10.1007/s00259-009-1097-x
- 253 Downloads
Angiotensin-converting enzyme (ACE) and soluble interleukin-2 receptor (sIL-2R) are serological markers, widely used for determining sarcoidosis activity. 18F-FDG PET has proven to be a sensitive technique in the imaging of sarcoidosis. The aim of this study was to determine sensitivity of 18F-FDG PET, genotype-corrected ACE and sIL-2R in active sarcoidosis as well as their correlation.
This retrospective study included 36 newly diagnosed, symptomatic sarcoidosis patients. ACE and sIL-2R levels were simultaneously obtained within 4 weeks of 18F-FDG PET. ACE was corrected for genotype and expressed as Z-score. 18F-FDG PET was visually evaluated and scored as positive or negative. Maximum and average standardized uptake values (SUVmax and SUVavg) were compared with ACE and sIL-2R.
18F-FDG PET was found positive in 34 of 36 patients (94%). Thirteen patients (36%) showed an increased ACE with the highest sensitivity found in patients with the I/I genotype (67%). Seventeen patients (47%) showed an increased sIL-2R. No correlation was found between SUV and ACE or sIL-2R. Increased ACE and sIL-2R correlated with a positive 18F-FDG PET in 12 patients (92%) and 16 patients (94%), respectively.
18F-FDG PET is a very sensitive technique to assess active sarcoidosis, in contrast with ACE and sIL-2R, suggesting a pivotal role for 18F-FDG PET in future sarcoidosis assessment.